- Home
- PIII vs EYEN Comparison
PIII vs EYEN Comparison
Compare PIII & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- EYEN
- Stock Information
- Founded
- PIII 2015
- EYEN 2014
- Country
- PIII United States
- EYEN United States
- Employees
- PIII N/A
- EYEN N/A
- Industry
- PIII Medical/Nursing Services
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- EYEN Health Care
- Exchange
- PIII Nasdaq
- EYEN Nasdaq
- Market Cap
- PIII 32.2M
- EYEN 9.2M
- IPO Year
- PIII N/A
- EYEN 2018
- Fundamental
- Price
- PIII $0.21
- EYEN $0.09
- Analyst Decision
- PIII Buy
- EYEN Hold
- Analyst Count
- PIII 3
- EYEN 4
- Target Price
- PIII $2.38
- EYEN $2.00
- AVG Volume (30 Days)
- PIII 336.1K
- EYEN 16.1M
- Earning Date
- PIII 11-12-2024
- EYEN 11-12-2024
- Dividend Yield
- PIII N/A
- EYEN N/A
- EPS Growth
- PIII N/A
- EYEN N/A
- EPS
- PIII N/A
- EYEN N/A
- Revenue
- PIII $1,476,630,000.00
- EYEN $31,832.00
- Revenue This Year
- PIII $21.45
- EYEN $23,413.60
- Revenue Next Year
- PIII N/A
- EYEN $400.98
- P/E Ratio
- PIII N/A
- EYEN N/A
- Revenue Growth
- PIII 25.38
- EYEN 2557.10
- 52 Week Low
- PIII $0.18
- EYEN $0.08
- 52 Week High
- PIII $1.78
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- PIII 40.98
- EYEN 29.89
- Support Level
- PIII $0.18
- EYEN $0.08
- Resistance Level
- PIII $0.23
- EYEN $0.10
- Average True Range (ATR)
- PIII 0.02
- EYEN 0.01
- MACD
- PIII 0.00
- EYEN 0.01
- Stochastic Oscillator
- PIII 38.24
- EYEN 18.08
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.